Int J Oral Biol.  2016 Sep;41(3):113-118. 10.11620/IJOB.2016.41.3.113.

Cellular Effects of Troglitazone on YD15 Tongue Carcinoma Cells

• Ta Thi L
• Yoo H

• KMID: 2354198
• DOI: http://doi.org/10.11620/IJOB.2016.41.3.113

Abstract

An FDA approved drug for the treatment of type II diabetes, Troglitazone (TRO), a peroxisome proliferator-activated receptor gamma agonist, is withdrawn due to severe idiosyncratic hepatotoxicity. In the search for new applications of TRO, we investigated the cellular effects of TRO on YD15 tongue carcinoma cells. TRO suppressed the growth of YD15 cells in the MTT assay. The inhibition of cell growth was accompanied by the induction of cell cycle arrest at G₀/G₁ and apoptosis, which are confirmed by flow cytometry and western blotting. TRO also suppressed the expression of cell cycle proteins such as cyclin D1, cdk2, cdk4, cyclin B1, cdk1(or cdc2), cyclin E1 and cyclin A. The inhibition of cell cycle proteins was coincident with the up-regulation of p21(CIP1/WAF1) and p27(KIP1). In addition, TRO induces the activation of caspase-3 and caspase-7, as well as the cleavage of PARP. Further, TRO suppressed the expressions of Bcl-2 without affecting the expressions of Bad and Bax. Overall, our data supports that TRO induces cell cycle arrest and apoptosis on YD15 cells.

Keyword

Cell cycle arrest; apoptosis; troglitazone; YD15 tongue carcinoma

MeSH Terms

Apoptosis
Blotting, Western
Caspase 3
Caspase 7
Cell Cycle Checkpoints
Cell Cycle Proteins
Cyclin A
Cyclin B1
Cyclin D1
Cyclins
Flow Cytometry
Peroxisomes
Tongue*
Up-Regulation
Caspase 3
Caspase 7
Cell Cycle Proteins
Cyclin A
Cyclin B1
Cyclin D1
Cyclins